-
Company Profile
![]()
Curevac NV – Company Profile
Curevac NV (Curevac) is a clinical-stage biopharmaceutical company that develops RNA-based medicines. The company develops, designs, and produces messenger rna molecules for therapeutic and prophylactic vaccines in the fields of oncology and infectious diseases. Its product pipeline includes Cv0501, Cv2cov, Flu Sv Mrna and Cvsqiv. Curevac mrna-based prophylactic vaccines candidates comprise cv7202 and cv8102. it also carries out the research and development. The company Cv8102, a lead oncology candidate is designed to modulate the tumor microenvironment. Its products are used...
Add to Basket -
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CVGBM in Astrocytoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. CVGBM in Astrocytoma Drug Details: The vaccine candidate is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CVGBM in Astrocytoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. CVGBM in Astrocytoma Drug Details: The vaccine candidate is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CVGBM in Glioblastoma Multiforme (GBM)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. CVGBM in Glioblastoma Multiforme (GBM) Drug Details: The vaccine candidate is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Cvsqiv in Seasonal Influenza
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.CVSQIV in Seasonal Influenza Drug Details:CVSQIV is under development for the prevention of seasonal influenza. The...
-
Track & Monitor
New![]()
Immuno-oncology in Pharmaceuticals: Cancer chimeric antigen receptor (CAR) T-cell therapy
Innovation in the pharmaceuticals industry is relentless, making it hard to stay-on top of the dynamically evolving industry landscape and in early identification of profound shifts, posing high risk of being disrupted if detected too late. GlobalData's coherent data-driven approach, using multiple forward-looking alternative datasets, empowers clients by decoding in advance the disruptive innovations in pharmaceuticals industry. Using patents data, GlobalData's proprietary industry innovation s-curve identifies specific innovation areas and their stage of evolution, i.e., whether they are emerging, accelerating...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – MBQ-167 in Triple-Negative Breast Cancer (TNBC)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.MBQ-167 in Triple-Negative Breast Cancer (TNBC) Drug Details:MBQ-167 is under development for the treatment of triple...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CAL-056 in Pancreatic Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.CAL-056 in Pancreatic CancerDrug Details:CAL-056 mesylate is under development for the treatment of resistant or refractory...
-
Product Insights
New![]()
Innovation in pharma: anti-RSV vaccines
Why settle for outdated information when you can stay ahead of the curve with our comprehensive report? Our team of industry experts has meticulously researched and analyzed the latest trends, innovations, and emerging technologies in the pharma industry’s anti-RSV vaccines innovations. By leveraging our report, you'll gain invaluable insights that can revolutionize your business strategies and give you a competitive edge. Why Choose Our Report? Unparalleled Expertise: Our research team consists of seasoned analysts with deep knowledge and experience in...
-
Product Insights
New![]()
Genomics in pharma: gene silencing
Why settle for outdated information when you can stay ahead of the curve with our comprehensive report? Our team of industry experts has meticulously researched and analyzed the latest trends, innovations, and emerging technologies in the pharma industry’s gene silencing within Genomics innovations. By leveraging our report, you'll gain invaluable insights that can revolutionize your business strategies and give you a competitive edge. Why Choose Our Report? Unparalleled Expertise: Our research team consists of seasoned analysts with deep knowledge and...
-
Product Insights
New![]()
Nanomedicine in pharma: mRNA delivery lipid nanoparticles
Why settle for outdated information when you can stay ahead of the curve with our comprehensive report? Our team of industry experts has meticulously researched and analyzed the latest trends, innovations, and emerging technologies in the pharma industry’s mRNA delivery lipid nanoparticles within Nanomedicine innovations. By leveraging our report, you'll gain invaluable insights that can revolutionize your business strategies and give you a competitive edge. Why Choose Our Report? Unparalleled Expertise: Our research team consists of seasoned analysts with deep...
-
Product Insights
New![]()
Cell & gene therapy in pharma: vascular disorder gene therapies
Why settle for outdated information when you can stay ahead of the curve with our comprehensive report? Our team of industry experts has meticulously researched and analyzed the latest trends, innovations, and emerging technologies in the pharma industry’s vascular disorder gene therapies within Cell & gene therapy innovations. By leveraging our report, you'll gain invaluable insights that can revolutionize your business strategies and give you a competitive edge. Why Choose Our Report? Unparalleled Expertise: Our research team consists of seasoned...
-
Sector Analysis
Coronavirus Disease 2019 (COVID-19) Analyst Consensus Sales Analysis and Forecast, H2 2022
COVID-19 Analyst Consensus Sales Report Overview Prophylactic COVID-19 vaccines are projected to generate total sales of $264 billion from 2021 to 2028. The number of COVID-19 drugs with forecast sales nearly tripled due to the massive mandatory vaccination campaigns led by the major markets, which caused rapid increases in COVID-19 vaccines. BioNTech/Pfizer’s Comirnaty, Moderna’s Spikevax, and Pfizer’s Paxlovid are the top three marketed drugs with the highest peak forecast sales. Comparing Q4 2020 and H2 2022 total COVID-19 forecast sales within...
-
Product Insights
Glioblastoma Multiforme (GBM) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Glioblastoma Multiforme Pipeline Drugs Market Glioblastoma also known as glioblastoma multiforme is a fast-growing glioma that develops from star-shaped glial cells that support the health of the nerve cells within the brain. Symptoms include headaches, blurred vision, nausea, vomiting, memory loss, speech difficulty, muscle weakness, and loss of appetite. Risk factors include gender (male) and age. Treatment includes surgery, radiation therapy, and chemotherapy. The Glioblastoma Multiforme (GBM) drugs in development market research report provides comprehensive information on the therapeutics under...
-
Product Insights
![]()
Net Present Value Model: Coronavirus Disease 2019 (COVID-19) vaccine
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Coronavirus Disease 2019 (COVID-19) vaccine Drug...
-
Product Insights
![]()
Net Present Value Model: CV-7202
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model CV-7202 Drug Details CV-7202 is under...
-
Product Insights
![]()
Net Present Value Model: CV-8102
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model CV-8102 Drug Details CV-8102 is under...
-
Product Insights
![]()
Net Present Value Model: BI-1361849
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model BI-1361849 Drug Details BI-1361849 (CV-9202) is...
-
Product Insights
![]()
Likelihood of Approval and Phase Transition Success Rate Model – FRAME-001
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry FRAME-001 Drug Details FRAME-001 is under development for the treatment of advanced non-small cell...
-
Product Insights
![]()
Likelihood of Approval and Phase Transition Success Rate Model – CVSQIV
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry CVSQIV Drug Details CVSQIV is under development for the prevention of seasonal influenza. The...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.